Yeah, you caught me ducking another question.
Actually I'm not critical of partnering 1127 yet. Of all the costim molecules out there, this one is certainly in the upper echelon in promise. it hasn't shown much when used alone (like the other costims) but there is a reason to believe it will in combination. Might as well wait and see it how well it plays with others before putting a value on it.
Now with rindo and glemba, the story is a bit different. Here CLDX stated they were seeking partners, and in fact were in frequent discussions. Posters here celebrated the news.
Then CLDX announced they were no longer seeking a partner. Posters here celebrated the news.
"HRC apparent TAX CHEAT---But what difference does it make?"
You would fit in well with these politicians, Frank. You should be discussing with the RNC your possible presidential bid.
Mostly just kidding long_ who finds something of value relative to CLDX in nearly every press release or journal article.
"my memory was decent and my reading capabilities and comprehension above what many on here post or understand"
your command of your native language is indeed impressive, damn near fluent.
I'm a little puzzled by why you feel the 10% royalty rate you originally remembered with no mention of other discounts is close to the actual 3% plus.
Right....before CLDX could have partnered with just AstraZeneca, now they can partner with AstraZeneca/Celgene. Twice as good!
Flattered you would ask, but have nothing to share now.
Even when what you write is supporting their pro-rindo belief!
It's even less barely relevant than you write. There was NO selection on either EGFR or EGFRVIII status. All it took to get into the study was a tumor type that often is EGFR amplified.
in any event, the data are two years old and ABBV has long ago moved on by turning this antbody into a ADC.
ABBV wasn't impressed with the results ether and so tacked a cytotoxic molecule on to it to form an ADC.
Now in a Phase I/II trial for GBM. Shows promise in the all-important rodent setting:
"ABT-414 is highly effective in both mutant and wild-type EGFR-positive human tumor xenografts in mice producing complete regressions and cures observed in the most sensitive models."
A definitive timeline:
1. 2005 Celldex kicked out of Medarex
2. "In November 2008, we entered into a license agreement with Southampton to develop human antibodies towards CD27"
3. Jul 23, 2009 - Bristol-Myers Squibb Co. said it agreed to buy Medarex Inc.
Only connection 1127 has to Medarex is the general antibody technology was licensed from Medarex as part of the spinout.
Unappreciated by most but it cracked me up!
You won't see keytruda+varli in the clinic anytime soon.
BTW...keytruda was fda approved before opdivo
"revealed last year to come out of the basic research labs at Celldex"
In 2006, Curagen announced it was developing this molecule based on Abgenix and Seattle Genetics technology:
CR014-vcMMAE for the treatment of cancer
In January 2006, we announced the advancement to preclinical development of CR014-vcMMAE, a fully-human monoclonal antibody that also utilizes ADC technology from Seattle Genetics, which we are evaluating as a potential treatment for ovarian cancer and renal cell carcinoma. CR014 targets TIM-1, also known as T-cell Immunoglobulin and Mucin domain 1, a protein expressed on the surface of certain cancer cells. In March 2006, we presented new preclinical data on CR014 at the 97th Annual Meeting of the AACR in Washington, D.C., that demonstrated significant anti-proliferative activity on antigen positive renal and ovarian carcinoma cell lines both in vitro and in vivo.
"Rindo will be administered immediately on diagnosis."
A couple of months after diagnosis following surgery and radiation treatment.
Not yet in primary.
Disease Status. Patients must have a resectable, recurrent supratentorial WHO Grade IV malignant glioma based on imaging studies with measurable disease (≥ 1 cm or ≤ 5 cm of contrast-enhancing tumor). Prior histopathology consistent with a World Health Organization (WHO) Grade IV malignant glioma confirmed by the study pathologist, Roger McLendon, or his designate
" ..and it doesn't therefore help if tumors reoccur or metastasize."
1. As was shown last night, the phase I trial is testing it in recurrent patients.
2. Only very rarely does glioblastoma metastasize.
1. "Most Promising Therapy I Have Seen in My Career"-- Henry S. Friedman (2015)
Discussing the PVS-RIPO, the oncolytic poliovirus recombinant under development at Duke
2. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9:4247–54
preclinical development of rindopepimut.
Some of the team working on the therapy shown last night, including Friedman who gave that bold answer, were also behind rindopepimut. They have a financial stake in both molecules. He is clearly saying he sees more promise in this therapy than he sees in rindo.
Now, of course, rindo could make it to market much faster than the virus, but it is important to remember that it could be made obsolete by stuff already in development (eg CAR-T, other oncolytic viruses)